Document:

<PAGE>

                                 EXHIBIT 10.23

February 6, 2001

Dickerson Wright
Chairman and Chief Executive Officer
U.S. Laboratories, Inc.
7895 Convoy Court, Suite 18
San Diego, CA  92111

     Re:  Investor Relations Agreement

Dear Dick:

This letter agreement contains the terms under which Pont Loma Partners, Inc.
("PLP") will provide services to U.S. Laboratories, Inc. ("USLB").  It is a
contract between PLP and USLB.  PLP and USLB will be referred to as a "Party" or
collectively, as the "Parties."  The relationship between the Parties is that of
independent contractor and nothing else.

1.  Services: USLB retains PLP to provide financial advisory and investor
    relations services. Among other duties, PLP shall introduce USLB to its
    contacts in the financial community and advise USLB on expanding its network
    of securities firms, stockbrokers, market makers, research analysts, and
    institutional and individual shareholders.

2.  Access to Information: USLB acknowledges that in order for PLP to
    successfully complete any aspect of this project, it must fully cooperate
    with PLP. On execution of this agreement, USLB agrees to promptly provide
    PLP with copies or make available the originals of all requested
    information. PLP agrees to keep all such information confidential until such
    time that USLB is authorized to release such information or required to do
    so by court of law.

3.  Confidentiality: The Parties may furnish each other confidential
    information. "Confidential Information" means all non-public business and
    technological information. Confidential Information does not include
    information that is public at the date of disclosure, information that is
    legally disclosed by a third party who is under no duty not to disclose the
    information, and information a Party knew before the disclosing Party
    disclosed that information publicly or directly to the receiving Party and
    provided the receiving party did not obtain that information illegally. The
    Parties agree to keep all Confidential Information confidential until it is
    no longer Confidential Information. The Parties agree to maintain the
    Confidential Information in strict confidence, not disclose it to any third
    party unless required in connection with obligations under this agreement.
    The Parties will require their officers, directors, employees, agents and
    representatives to similarly restrict disclosure and use. The Parties are
    responsible for any wrongful disclosure by its employees, officers,
    directors and agents. If any court
<PAGE>

Investor Relations Agreement
February 6, 2001
Page 2 of 4

    or other authority orders disclosure of Confidential Information, the
    Parties will use their best efforts to protect confidentiality and
    immediately notify the disclosing Party so that it may also take actions to
    preserve confidentiality.

4.  Expenses: USLB agrees to reimburse PLP for all reasonable out-of-pocket
    expenses. PLP will periodically bill USLB for all expenses as they are
    incurred. PLP agrees that any single expense of $500.00 or more will require
    advance approval from USLB before the expense is incurred.

5.  Non-Circumvention: USLB agrees that all information relating to potential
    business opportunities identified by PLP and the contacts identified by PLP
    relating to such opportunities are Confidential Information and will not be
    shared by USLB with any other party without advance written consent of PLP.
    The Parties agree that any transaction with any such contact without the
    participation of PLP before or after termination of this Letter Agreement
    must include competitive compensation for PLP.

6.  Cash Compensation: USLB will pay to PLP $3,000 per month in advance.
    Payments shall be due on the 15th of each month. This Agreement will
    commence and the first payment will be due on February 15, 2001.

7.  Equity Compensation:  USLB will grant the following stock purchase warrants
    to PLP per the following terms:

    a.  $40,000 common stock purchase warrants with a strike price of $4.50 to
        be granted immediately upon the execution of this Agreement.

    b.  40,000 common stock purchase warrants with a strike price of $4.50 to be
        granted immediately, yet exercisable only if the closing bid price of
        USLB exceeds $6.00 for 20 consecutive trading days.

    c.  40,000 common stock purchase warrants with a strike price of $4.50 to be
        granted immediately, yet exercisable only if the closing bid price of
        USLB exceeds $8.00 for 20 consecutive trading days.

    d.  The above stock purchase warrants will expire three (3) years from the
        date they are granted.

8.  Term of Engagement:  The term of this Agreement shall be one (1) year and
    will commence on February 15, 2001.

9.  Limitation of Liability: Neither PLP, nor its affiliates, licensors,
    contractors, representatives or agents will be liable to USLB for any
    indirect, incidental, special, consequential, exemplary or punitive damages
    arising from, connected with or relating to this letter agreement. This
    include any lost profits or revenues, lost savings, or other similar
    damages. Under no circumstances will PLP's liability ever exceed the amount
    paid to it by USLB excluding expense reimbursement. Each party recognizes
    and agrees that the warranty disclaimers and liability and remedy
    limitations in this

                                      2

<PAGE>

Investor Relations Agreement
February 6, 2001
Page 3 of 4

    agreement are material bargained for terms of this agreement. They take into
    account and reflect the consideration given by each party pursuant to this
    agreement and the decision by each party to enter into this agreement.

10. Arbitration: The Parties agree to resolve all claims, dispute and
    controversies past, present or future arising out of or related to, this
    letter agreement against each and against respective officers, directors,
    agents and employees in final and binding arbitration in San Diego,
    California under the rules of the American Arbitration Association ("AAA").
    The Parties agree to waive any rights to trial by jury, adjudication in a
    different venue and notice requirements. The arbitrator will be an
    individual knowledgeable about the subject matter of the dispute mutually
    agreed upon by the Parties from a AAA panel. If the Parties cannot agree on
    an arbitrator, each Party will select an individual from the AAA list, and
    the two so selected will choose the arbitrator from another AAA panel. The
    arbitrator will apply the substantive law of California without regard to
    the principles of conflicts of law or U.S. law, as applicable. The
    arbitrator will have the exclusive authority to resolve disputes relating to
    interpretation, applicability and enforcement of this letter agreement. Each
    Party agrees to split the cost of arbitration excluding legal fees. The
    arbitration process, including selection of the arbitrator, exchange of
    requests for information and the arbitration hearing will be completed
    within 60 days following the institution of the arbitration by a party, and
    the actual arbitration hearing shall be limited to 1 day. The parties may
    enter judgment on any arbitration award in any court having jurisdiction.
    This paragraph shall survive termination of this agreement. Both arbitrators
    and courts of law shall award all costs (excluding arbitration costs) and
    reasonable attorney fees to the prevailing party in any arbitration or
    litigation.

11. No Waiver: The Parties will not treat any failure to object to any terms of
    this agreement as a waiver of those terms. Consent or approval on any one
    occasion does not mean consent on any other item or any other time.

12. Governing Law: This letter agreement shall be interpreted equally as to all
    Parties. It will be governed by the laws of the State of California without
    giving effect to choice of law provisions.

13. Severability: If an arbitrator or court of competent jurisdiction determines
    any part of this agreement invalid or unenforceable, and the decision is not
    subject to appeal, the Parties agree that the particular part will be deemed
    severed. If a term is invalid because of its scope, the term will be deemed
    valid to the extent of the scope permitted by applicable law. This letter
    agreement will be binding on successors and assigns.

14. Notification: Should a Party have to notify the other for any reason that
    Party agrees to do so in writing delivered personally, by mail or by
    reputable overnight delivery service. Notification shall be delivered to the
    following addresses:

                                       3
<PAGE>

Investor Relations Agreement
February 6, 2001
Page 4 of 4

          If to PLP:   Jeffrey J. Janda, Chief Executive Officer
                       Point Loma Partners, Inc.
                       701 B. Street, Ste. 1400
                       San Diego, California 92101

          If to USLB:  Dickerson Wright
                       Chairman and Chief Executive Officer
                       U.S. Laboratories, Inc.
                       7895 Convoy Court, Suite 18
                       San Diego, CA 92111

          The Parties can change these addresses by notifying each other in
          writing in accordance with the terms of this agreement.

If USLB wishes to be a Party to this letter agreement, and be bound by its
terms, please have an authorized representative on the approval page (signature
line provided below).  USLB should return a signed copy of this Agreement to PLP
together with a check in the amount of $3,000.00.

Sincerely,

/s/ Jeffrey J. Janda

Jeffrey J. Janda
Chief Executive Officer
Point Loma Partners, Inc.

ACKNOWLEDGEMENT AND APPROVAL:

We have read this five (5) page letter agreement.  We understand and accept its
contents.  We, the undersigned, also represent that we are authorized to sign on
behalf of our respective Parties and authorized to bind our respective Parties
to the provisions of this letter agreement.

Point Loma Partners, Inc.                      U.S. Laboratories, Inc.

By:  /s/ Jeffrey J. Janda                      By:  /s/ Dickerson Wright
   ---------------------------                         ------------------------
Name:  Jeffrey J. Janda                        Name:  Dickerson Wright

Title:  Chief Executive Officer                Title:  Chief Executive Officer

Date:  February 15, 2001                       Date:  February 15, 2001

                                       4
<PAGE>

                           POINT LOMA PARTNERS, INC.
                           701 B Street, Suite 1400
                             San Diego, CA  92101
                                (619) 233-0726

February 9, 2001

Dickerson Wright
Chairman and Chief Executive Officer
U.S. Laboratories, Inc.
7895 Convoy Court, Suite 18
San Diego, CA  92111

     Re:  Amendment to Investor Relations Agreement ("Amendment")

Dear Dick,

With respect to our Letter Agreement re: Investor Relations Agreement (the
"Original Agreement"), we have agreed to amend the Original Agreement as
follows:

1)  We hereby confirm that the date of the Original Agreement shall be as of
    February 6, 2001, the date on the first page of the Original Agreement.

2)  Section 5 of the Original Agreement, "Non-Circumvention," is hereby amended
    to read in its entirety:

               "Non-Circumvention:  USLB agrees that all information relating to
               potential business opportunities identified by PLP and the
               contacts identified by PLP relating to such opportunities are
               Confidential Information and will not be shared by USLB with any
               other party without advance written consent of PLP.  The Parties
               agree that any transaction before or after termination of this
               Letter Agreement with any such contact without the participation
               of PLP must include competitive compensation for PLP."

3)  Section 8 of the Original Agreement, "Term of Engagement", is hereby amended
    to read in its entirety: "The term of this Agreement shall commence on
    February 6, 2001 and end on February 9, 2003."
<PAGE>

IR Agreement Amendment
Februray 9, 2001
Page 2 of 3

4)  The equity compensation described in Section 7 of the Original Agreement
    shall be deleted in its entirety, and replaced by Sections 4, 5 and 6 of
    this Amendment.

5)  A warrant to purchase 65,000 shares of common stock at $4.50 per share,
    shall be granted and fully vested as of the date hereof. This warrant shall
    expire on February 8, 2004. U.S. Laboratories, Inc. ("USLB") hereby agrees
    to register the shares underlying this warrant in its upcoming registration
    statement.

6)  A second warrant to purchase 30,000 shares of common stock at $4.50 per
    share shall be granted by USLB to Point Loma Partners, Inc. ("PLP") on
    February 9, 2002 at the sole discretion of USLB if it deems that PLP has
    faithfully performed its duties. If so granted, this warrant shall expire on
    February 8, 2005. If so granted, USLB hereby agrees to include the shares
    issuable upon exercise of this warrant in any registration statement filed
    after February 9, 2002.

7)  A third warrant to purchase 25,000 shares of common stock at $7.00 per share
    shall be granted by USLB to PLP on February 8, 2003 at the sole discretion
    of USLB if it deems that PLP has faithfully performed its duties. If so
    granted, this warrant shall expire on February 7, 2006. If so granted, USLB
    hereby agrees to include the shares issuable upon exercise of this warrant
    in any registration statement filed after February 8, 2003.

8)  If PLP terminates or otherwise materially defaults under the Original
    Agreement, as amended by the terms of this Amendment (as may be further
    amended, the "Agreement") for any reason, then 50% of the cash payments
    received through the date of such termination shall be refunded promptly to
    USLB.

9)  Both parties acknowledge that the Original Agreement was in error,
    necessitating the changes set forth in this Agreement.

10) The Original Agreement shall remain in effect except as modified by the
    terms of this Amendment.

11) The parties represent to each other that the person signing below is
    authorized to sign on behalf of the respective parties to this Amendment and
    is authorized to bind such party to the provisions of this Amendment.

12) PLP hereby represents that (i) it is an accredited investor as such term is
    defined in Rule 501 promulgated under the Securities Act of 1933, as
    amended, and (ii) it is acquiring the warrant granted as of the date hereof
    for investment purposes only and not with a view towards resale or
    distribution.
<PAGE>

IR Agreement Amendment
Februray 9, 2001
Page 3 of 3

13) Each warrant granted pursuant to Section 4, 5 or 6 of this Letter Agreement
    shall be in substantially the same form as that certain Common Stock
    Purchase Warrant between USLB and Miller Capital Corporation, dated March
    15, 1998. Any such Warrant Agreement shall supersede any conflicting
    provision in the Agreement.

14) The parties may not assign their rights or obligations under the Agreement
    without the written counsel of the other party.

If you understand the above and it is acceptable to you, please sign the
attached acknowledgement where indicated and return a copy of this letter to me.

Thank you.

Sincerely,

/S/ JEFFREY J. JANDA

Jeffrey J. Janda
Chief Executive Officer
Point Loma Partners, Inc.

ACKNOWLEDGEMENT AND APPROVAL:

IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the 9th
day of February, 2001.

Point Loma Partners, Inc.                     U.S. Laboratories, Inc.

/S/ JEFFREY J. JANDA                          /S/ DICKERSON WRIGHT

Name:  Jeffrey J. Janda                       Name:  Dickerson Wright

Title:  Chief Executive Officer               Title:  Chief Executive Officer<PAGE>

                                 EXHIBIT 10.24

The warrant represented by this certificate and the shares available upon
exercise hereof have not been registered under the Securities Act of 1933, as
amended, and may not be sold, pledged, or otherwise transferred unless (1)
covered by an effective registration statement under the Securities Act of 1933,
as amended, or (2) U. S. Laboratories Inc. has been furnished an opinion of
counsel acceptable to it to the effect that no registration is legally required
for such transfer.

Date of Issuance: February 9, 2001            Warrant To Purchase
                                              65,000 Shares of Common Stock as
                                              Herein Described

                             U.S. LABORATORIES INC.

                         COMMON STOCK PURCHASE WARRANT

     THIS AGREEMENT is made as of February 9, 2001 (the "Grant Date"), by and
between U.S. Laboratories Inc., a Delaware corporation (the "Company"), and
Point Loma Partners, Inc., an Arizona corporation (the "Holder").

                                    RECITALS
                                    --------

     WHEREAS, the Board of Directors of the Company (the "Board") approved the
grant of a warrant to purchase shares of the Company's common stock, par value
$ .01 per share ("Stock"), to the Holder; and

     WHEREAS, the Company and Holder have entered into that Investor Relations
Agreement dated as of February 6, 2001, as amended as of February 9, 2001 (the
"Investor Relations Agreement"); and

     WHEREAS, this Agreement is intended to memorialize the terms and conditions
of such grant.

                                   AGREEMENT
                                   ---------

     NOW, THEREFORE, in consideration of the covenants and agreements herein set
forth, the parties hereby mutually covenant and agree as follows:

          1.  Grant.  The Company hereby grants to Holder a warrant to purchase
              -----
     from the Company all or any part of an aggregate number of sixty-five
     thousand (65,000) shares of Stock (hereinafter such shares of Stock are
     referred to as the "Warrant Shares" and the warrant to purchase the Warrant
     Shares is referred to as the "Warrant").
<PAGE>

          2.  Price.  The price to be paid for the Warrant Shares shall be $4.50
              -----
     per share.

          3.   Term: Exercise.
               --------------

               (a) This Warrant may be exercised immediately by the Holder
          hereof in whole or in part, from time to time.

               (b) This Warrant will expire at 11:59 p.m., Eastern time, on
          February 8, 2004.

          4.  Method of Exercise.  The Warrant may be exercised only by written
              ------------------
     notice, delivered or mailed by postpaid registered or certified mail,
     addressed to the treasurer of the Company at the Company's principal
     executive offices specifying the number of Warranted Shares being
     purchased.  Such notice shall be accompanied by payment of the entire price
     of the Warrant Shares being purchased (i) in cash or its equivalent, (ii)
     by tendering previously acquired shares of Stock having a fair market value
     (as determined by the Board) equal to the price of the Warrant Shares being
     purchased, or (iii) by a combination of (i) and (ii).  The Warrant may be
     exercised in the manner previously described or by delivery to the Company
     or its designated agent of an executed irrevocable exercise form together
     with instructions to a broker-dealer to sell or margin a sufficient portion
     of the shares being exercised and deliver the sale or margin proceeds
     directly to the Company to pay for price for the Warrant Shares.  Upon
     receipt of the payment of the entire price of the Warrant Shares so
     purchased, certificates for such Warrant Shares shall be issued to the
     Holder.  The Warrant Shares so purchased shall be fully paid and
     nonassessable.

          5.  No Rights as a Stockholder.  The Holder shall not be deemed for
              --------------------------
     any purposes to be a stockholder of the Company with respect to any shares
     which may be acquired hereunder except to the extent that the Warrant shall
     have been exercised with respect thereto and a stock certificate issued
     therefor.

          6.  Transferability.  The Warrant may be transferred by the Holder as
              ---------------
     long as any transferee agrees to be bound by this Agreement.

          7.  Restrictions on Transfers of Stock.  The shares to be acquired
              ----------------------------------
     upon exercise of the Warrant may not be sold or offered for sale except (i)
     pursuant to an effective registration statement under the Securities Act of
     1933 (the "Act") or any applicable state securities laws, (ii) in a
     transaction satisfying the requirements of Rule 144 promulgated under the
     Act, or (iii) in a transaction which, in the opinion of counsel for the
     Company, is exempt from the, registration provisions of the Act or
     applicable state securities laws.  Any certificate representing shares
     acquired upon exercise of the Warrant may bear the following legend:

               The shares of Common Stock represented by this certificate are
               restricted securities as that term is defined under Rule

                                       2
<PAGE>

               144 promulgated under the Securities Act of 1933, as amended (the
               "Act"). These shares may not be sold, transferred or disposed of
               unless they are registered under the Act, sold in a transaction
               satisfying the requirements o f Rule 144 or unless the request to
               transfer is accompanied by an opinion of counsel acceptable to
               the issuer, that the transfer will not result in a violation of
               the Act or any applicable state securities laws.

          8.  Specific Retrictions Upon Warrant Shares.  The Holder shall
              ----------------------------------------
     acquire the Warrant Shares for investment purposes only and not with a view
     to resale or other distribution thereof to the public in violation of the
     Act, and shall not dispose of the Warrant Shares in any transaction which,
     in the opinion of counsel to the Company, would violate the Act, or the
     rules and regulations thereunder, or any applicable state securities or
     blue sky laws.

          9.  Adjustments.  If the Company changes the number of shares of its
              -----------
     Stock without new consideration to the Company (such as by stock dividend,
     stock split or similar transaction), the total number of shares then
     remaining subject to purchase hereunder shall be changed in proportion to
     the change in issued shares, and the Warrant price per share shall be
     adjusted so that the total consideration payable to the Company upon the
     purchase of all shares not theretofore purchased shall not be changed.  If
     there is any change, other than as specified above, in the number or kind
     of outstanding shares of Stock or of any stock or other securities into
     which such Stock shall have been changed or for which it shall have been
     exchanged, then if the Board in its sole discretion determines that such
     change equitably requires an adjustment in the number or kind of shares
     subject to the Warrant, such adjustment shall be made by the Board.  The
     Warrant price for each share of Stock or other securities substituted or
     adjusted as provided in this paragraph shall be determined by dividing the
     Warrant price for each share prior to such substitution or adjustment by
     the number of shares or the fraction of a share substituted for such share
     or to which such share shall have been adjusted. No adjustment or
     substitution provided for in this paragraph shall require the Company to
     sell a fractional share.

          10.   Investment Representations.  Holder understands that the
                --------------------------
     Warrants and the Warrant Shares have not been registered under the Act.
     Holder also understands that the Warrant is being offered and sold pursuant
     to an exemption from registration contained in the Securities Act based in
     part upon Holder's representations contained in this Warrant.  Holder
     hereby represents and warrants as follows:

          (a) Holder Bears Economic Risk.  Holder has substantial experience in
     evaluating and investing in private placement transactions of securities in
     companies similar to the Company so that it is capable of evaluating the
     merits and risks of its investment in the Company and has the capacity to
     protect its own interests.  Holder must bear the economic risk of this
     investment indefinitely unless the Warrant or the Warrant Shares, as
     applicable, are registered pursuant to the Securities Act, or an exemption
     from

                                       3
<PAGE>

     registration is available. Holder understands that the Company has no
     present intention of registering the Warrant, the Warrant Shares or any
     other shares of its Common Stock. Holder also understands that there is no
     assurance that any exemption from registration under the Securities Act
     will be available and that, even if available, such exemption may not allow
     Holder to transfer all or any portion of the Warrant or the Warrant Shares
     under the circumstances, in the amounts or at the times Holder might
     propose.

          (b) Acquisition for Own Account.  Holder is acquiring the Warrant, and
     will acquire the Warrant Shares if the Warrant is exercised, for Holder's
     own account for investment only, and not with a view towards their
     distribution.

          (c) Holder Can Protect Its Interest.  By reason of its, or of its
     management's, business or financial experiences, Holder has the capacity to
     protect its own interests in connection with the transactions contemplated
     in this Warrant. Further, Holder is aware of no publication of any
     advertisement in connection with the transactions contemplated in this
     Warrant.

          (d)  Accredited Investor.  Holder represents that it is an accredited
     investor within the meaning of Regulation D under the Securities Act.

          (e) Company Information.  Holder has received and read the Company's
     financial statements and all documents that Holder considers material to
     its investment decision, and has had an opportunity to discuss the
     Company's business, management and financial affairs with directors,
     officers and management of the Company and has had the opportunity to
     review the Company's operations and facilities.  Holder has also I had the
     opportunity to ask questions of, and receive answers from, the Company and
     its management regarding the terms and conditions of this investment.

          (f) Rule 144.  Holder acknowledges that the Warrant and the Warrant
     Shares, as applicable, must be held indefinitely unless they are
     subsequently registered under the Securities Act or an exemption from such
     registration is available.  Holder -has been advised or is aware of the
     provisions of Rule 144 promulgated under the Securities Act, which permits
     limited resale of securities purchased in a private placement subject to
     the satisfaction of certain conditions, including, among other things: the
     availability of certain current public information about the Company, the
     resale occurring not less than two years after a party has purchased and
     paid for the security to be sold, the sale being through an unsolicited
     "broker's transaction" or in transactions directly with a market maker (as
     said term is defined under the Securities Exchange Act of 1934, as amended)
     and the number of shares being sold during any three-month period not
     exceeding specified limitations.

          (g)  Residence.  The office or offices of Holder in which its
     investment decision was made is located at the address of Holder set forth
     herein.

          11.  Registration Rights.  The Company hereby grants to Holder
               -------------------
     piggyback registration rights with respect to the Warrant Shares.  If the
     Company is filing a

                                       4
<PAGE>

     registration statement with the Securities and Exchange Commission for
     itself or on behalf of any of its stockholders, the Company will notify
     Holder in writing reasonably in advance of the filing (but at least five
     business days) and give Holder the opportunity to include all or any party
     of the Warrant Shares (whether or not previously issued, to the extent
     permissible under the Act or any regulation promulgated thereunder). Upon
     Holder's notification that Holder desires to have all or any portion of the
     Warrant Shares included in the registration, the Company will, at no cost
     or expense to the Holder, include or cause to be included in the
     registration statement the Warrant Shares so identified by Holder.
     Notwithstanding any other provision of this Section 11, in the case of an
     underwritten public offering, if the managing underwriter determines that
     market factors require a limitation of the number of shares to be
     underwritten, the managing underwriter may limit, or exclude entirely, the
     number of shares (including those of Holder) to be included in the
     piggyback registration. If limited, Holder's shares will be registered pro
     rata with any other holders of common stock or common stock equivalents
     having registration rights.

          12.  Tax Withholding.  The Company may withhold such amount as may be
               ---------------
     requested by the Company for the purpose of satisfying its liability to
     withhold federal, state or local income or other taxes incurred by reason
     of the exercise of the Warrant.  If the Holder fails to comply with this
     Paragraph 10, the Company may refuse to issue or transfer shares of Stock
     upon exercise of the Warrant.

          13.  Powers of Company Not Affected.  The existence of the Warrant
               ------------------------------
     herein granted shall not affect in any way the right or power of the
     Company or its stockholders to make or authorize any or all adjustments,
     recapitalizations, reorganizations or other changes in the Company's
     capital structure or its business, or any merger or consolidation of the
     Company, or any issuance of bonds, debentures, preferred, or prior
     preference stock ahead of or affecting the Stock or the rights thereof, or
     dissolution or liquidation of the Company, or any sale or transfer of all
     or any part of its assets or business , or any other corporate act or
     proceeding, whether of a similar character or otherwise.

          14.  Amendment or Modification.  No term or provision of this
               -------------------------
     Agreement may be amended, modified or supplemented orally, but only by an
     instrument in writing signed by the party against whom or which the
     enforcement of the amendment, modification or supplement is sought.

          15.  Governing Law.  This Agreement is governed by the internal laws
               -------------
     of the State of Delaware as to all matters, including, but not limited to,
     matters of validity , construction, effect, performance and remedies.

          16.  Entire Agreement.  This Agreement entered into between the Holder
               ----------------
     and the Company sets forth the entire agreement of the parties hereto in
     respect of the subject matter contained herein and supersedes all prior
     agreements, promises, covenants , arrangements, communications,
     representations or warranties, whether oral or written, by any officer,
     employee or representative of any party hereto; and any prior agreement of

                                       5
<PAGE>

     the parties hereto in respect of the subject matter contained herein is
     hereby terminated and canceled.

          17.  Delegation by Board.  Except to the extent prohibited by
               -------------------
     applicable law or the applicable rules of a stock exchange or market, the
     Board may delegate all or any portion of its responsibilities and powers to
     anyone or more of its members. Any such delegation may be revoked by the
     Board at any time.

          18.  Heirs and Successors.  This Agreement is binding upon, and inures
               --------------------
     to the benefit of, the Company and its successors and assigns, and upon any
     person acquiring all or substantially all of the Company's assets and
     business. If the Holder is an individual who dies prior to exercise of the
     Warrant, the Warrant may be exercised by the estate of the Holder if such
     exercise is otherwise permitted by this Agreement.

            IN WITNESS WHEREOF, the Company has caused this instrument to be
     executed by its duly authorized officer and the Holder has executed this
     Agreement as of the day and year first above written.

                                   U.S. LABORATORIES INC.

                                    By:_________________________________
                                         Dickerson Wright, President

                                    POINT LOMA PARTNERS, INC.

                                    By:__________________________________
                                          Jeffrey J. Janda, President

                                       6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00024-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00024-of-00352.parquet"}]]